NL-OMON48234
Completed
Not Applicable
BioMonitor III: Validation of the Atrial fibrillation Detecting algorithm in patients undergoing pulmonary vein isolation - BioVAD study
Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites30 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 30
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational invasive
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •1\. Diagnosis of paroxysmal or persistent AF as defined by the 2016 ESC
- •guidelines for the management of atrial fibrillation
- •2\. Subject scheduled to undergo PVI within 6 months
- •3\. Subject willing and able to comply with the follow\-up requirements of the
- •4\. Written informed consent obtained from subject aged 18 years or older
Exclusion Criteria
- •1\. Diagnosis of long\-standing persistent AF as defined by the 2016 ESC
- •guidelines for the management of atrial fibrillation
- •2\. Subjects implanted with a previous ICM, pacemaker, ICD, or cardiac
- •resynchronization therapy device
- •3\. Subjects with an active infection
- •4\. Subjects enrolled in another clinical study which may confound the results
- •of this study
- •5\. Subjects with a life expectancy of \<1 year due to any condition
Investigators
Similar Trials
Not yet recruiting
Not Applicable
BioMonitor III: Validation of the Atrial fibrillation Detecting algorithm in patients undergoing pulmonary vein isolatioParoxysmal and persistent atrial fibrillationNL-OMON23516Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands30
Active, not recruiting
Not Applicable
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2012-005086-12-HUOctapharma AG216
Active, not recruiting
Not Applicable
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globuliEUCTR2012-005086-12-ATOctapharma AG216
Active, not recruiting
Not Applicable
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 18.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2012-005086-12-BGOctapharma AG234
Active, not recruiting
Not Applicable
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2012-005086-12-DEOctapharma AG216